Immunotec
TINA.org investigated Immunotec as part of its larger investigations into unsubstantiated disease-treatment claims and atypical income claims used by MLM companies.
To read more about TINA.org’s 2023 MLM Income Claims Investigation, click here.
To read more about TINA.org’s 2017 DSA Income Claims Investigation, click here.
To read more about TINA.org’s 2016 DSA Health Claims Investigation, click here.
Timeline
2024
February 14
As part of its 2023 investigation into 100 MLM companies, TINA.org notifies Immunotec of its findings that the company has used atypical income claims to market its business opportunity.
2022
January 6
The DSSRC issues a case decision finding that Immunotec used unsubstantiated disease-treatment claims to market its products, including that they can help with infertility, autism, cancer, and pneumonia, among other conditions, and atypical earnings claims to market its business opportunity, including the ability to earn immediate and long-term income. According to the DSSRC, the company removed several posts at issue, prompting the DSSRC to close its investigation.
2018
January 15
Immunotec responds to TINA.org stating that it is taking steps to remove the deceptive income claims identified.
2017
December 18
As part of its 2017 investigation into all DSA-member companies, TINA.org notifies Immunotec of findings that it uses atypical income claims to market the business opportunity.
2016
December 12
Immunotec responds to TINA.org stating that it is taking steps to remove the deceptive health claims identified.
November 22
As part of its 2016 investigation into DSA-member companies that sell nutritional supplements, TINA.org notifies Immunotec of findings that it uses unsubstantiated disease-treatment claims to market its products.
The Latest
MLMs Continue to Recruit with Deceptive Earnings Claims
TINA.org investigation finds 98% of MLMs using misleading income claims.